Intracoronary stents

Uren, Neal; Chronos, N.

doi:10.1136/bmj.313.7062.892

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because early studies reported high rates of stent thrombosis, 34,35 aggressive antiplatelet and anticoagulant therapy, incorporating anticoagulation with heparin for up to 96 hours after deployment, was introduced to prevent these potentially fatal complications. 36 For the first few years that stents were being used, patients were given aspirin, dipyridamole, dextran, heparin, warfarin and calcium antagonists or a similar combination. The use of these regimens in early stent trials resulted in more bleeding complications and longer hospital stays with stents than with PTCA alone.…”

Section: Antithrombotic Therapy In Stent Usementioning

confidence: 99%

Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.

Meads

Cummins²,

Jolly³

et al. 2000

Health Technology Assessment

121

View full text Add to dashboard Cite

artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4(23). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA Programme T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources. The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA). The research reported in this monograph was commissioned by the HTA programme (project number 99/15/01) on behalf of the National Institute for Clinical Excellence (NICE). Rapid reviews are completed in a limited time to inform the appraisal and guideline development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidelines produced by NICE are informed by a wide range of sources. Any views expressed in this rapid review are therefore those of the authors and not necessarily those of the HTA programme, NICE or the Department of Health. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. Criteria for inclusion in the HTA monograph series Reports are published in the HTA monograph series if (1) they have resulted from work either prioritised by the Standing Group on Health Technology, or otherwise commissioned for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

Section: Antithrombotic Therapy In Stent Usementioning

confidence: 99%